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Background: Vascular factors including medical his-
tory (heart disease, stroke, diabetes, and hypertension),
smoking, and prediagnosis blood lipid measurements
(cholesterol: total, high-density lipoprotein, low-
density lipoprotein [LDL-C], and triglyceride concen-
trations) may be predictors for progression of Alzhei-
mer disease (AD).
Objective: To determine whether prediagnosis vascu-
lar risk factors are associated with progression of AD.
Design: Inception cohort followed up longitudinally for
a mean of 3.5 (up to 10.2) years.
Setting: Washington Heights/Inwood Columbia Aging
Project, New York, New York.
Patients: One hundred fifty-six patients with incident
AD (mean age at diagnosis, 83 years).
MainOutcomeMeasure: Change in a composite score
of cognitive ability from diagnosis onward.
Results: In generalized estimating equation models (ad-
justed for age, race/ethnicity, and years of education), higher
cholesterol (total cholesterol and LDL-C) concentrations
and history of diabetes were associated with faster cogni-
tive decline. Each 10-U increase in cholesterol and LDL-C
was associated with a 0.10-SD decrease in cognitive score
per year of follow-up (P.001 for total cholesterol;P=.001
for LDL-C). High-density lipoprotein cholesterol and tri-
glyceride concentrations were not associated with rate of
decline. A history of diabetes was associated with an ad-
ditional 0.05-SD decrease in cognitive score per year
(P=.05). History of heart disease and stroke were associ-
ated with cognitive decline only in carriers of the apolipo-
protein E ε4 (APOE-ε4) gene. In a final generalized esti-
mating equation model that included high-density
lipoprotein cholesterol and LDL-C concentrations and his-
tory of diabetes, only higher LDL-C was independently as-
sociated with faster cognitive decline.
Conclusion: Higher prediagnosis total cholesterol and
LDL-C concentrations and history of diabetes were as-
sociated with faster cognitive decline in patients with in-
cident AD, which provides further evidence for the role
of vascular risk factors in the course of AD.
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F EW TREATMENT OPTIONS AREavailable to improve theprognosis in patients withAlzheimer disease (AD).Controlling vascular condi-
tions may be one way of delaying the dis-
ease course. Vascular risk factors and vas-
cular disease are associated with higher risk
of vascular dementia1,2 and AD.3,4 Mem-
bers of our group previously reported as-
sociations between stroke,5 hyperinsu-
linemia,6 diabetes mellitus,7 current
smoking,8 and hypertension9 and higher
risk of AD. We found that high total
cholesterol and low-density lipoprotein
cholesterol (LDL-C) concentrations are
related to increased risk of vascular de-
mentia10,11 but not AD.
While vascular risk factors have been
studied as predictors of AD,4,12 few stud-
ies have assessed their influence on dis-
ease progression.13,14 We examined the in-
terplay between vascular factors and course
of AD in participants from the Washing-
ton Heights/Inwood Columbia Aging
Project, a multiethnic, community-
based, prospective study of aging in north-
ern Manhattan (New York, New York).
METHODS
PARTICIPANTS
Participants in the Washington Heights/
Inwood Columbia Aging Project are from 2
population-based cohorts of Medicare enroll-
ees. Recruitment for the first cohort began in
January 1992. The study area comprised 41 cen-
sus tracts in Manhattan between 155th Street and
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study area were obtained from the Health Care Financing Ad-
ministration. Potential participants were selected by systematic
random sampling into 1 of 6 strata on the basis of race/ethnicity
(Hispanic, non-Hispanic black, and non-Hispanic white) and age
(65-74 or 75 years). At baseline, 2125 subjects were inter-
viewed. A cohort of 2183 additional participants was formed in
November 1999 using similar methods with several exceptions:
new lists of beneficiaries were obtained but those drawn into the
1992 cohort were excluded, subjects who reported receiving a
diagnosis of dementia in the course of arranging for the initial
evaluation were excluded, and the study area was extended to en-
compass Manhattan north of 145th Street.
The sample for this analysis was restricted to individuals with
lipid assessments before diagnosis of dementia. During follow-
up, 417 individuals developed AD. Of these, prediagnosis vas-
cular risk factor data were available for 319, 156 of whom also
had postdiagnosis follow-up data (Figure). Of the individu-
als with incident AD with vascular risk factors, 44 (14%) died,
55 (17%) received the diagnosis in the most recent interview
wave and, therefore, had no postdiagnosis data available, and
64 (20%) were not followed up because of refusal or study drop-
out. Excluded patients with AD were similar to the analysis
sample insofar as age, sex, race/ethnicity; cognitive status at di-
agnosis; APOE-ε4 status; total cholesterol, high-density lipo-
protein cholesterol (HDL-C), and LDL concentrations; and pres-
ence of hypertension, stroke, and heart disease. However,
excluded participants had achieved higher educational levels
(8.1 vs 6.6 years; P=.002), had a higher prevalence of diabetes
(29% vs 18% of the analysis; P=.02), and had lower triglycer-
ide concentrations (mean, 154.9 vs 173.2 mg/dL; P=.04) (to
convert to millimoles per liter, multiply by 1.8).
The study was approved by the Columbia University Insti-
tutional Review Board. Written informed consent was ob-
tained from all subjects.
ASSESSMENT OF INCIDENT AD
Alzheimer disease was diagnosed using physician-
administered physical and neurologic examinations along with
a standardized neuropsychologic battery of tests.15 All assess-
ments were administered at baseline and at follow-up visits,
which occurred at approximately 18-month intervals. Evalu-
ations were conducted in English or Spanish according to
participant preference. All available information including
medical records and imaging studies was considered in the
evaluations.
Consensus diagnosis of dementia was made at conferences at-
tended by neurologists and neuropsychologists using the neuro-
psychologic battery of tests and evidence of social or occupa-
tional functional deficits per Diagnostic and Statistical Manual of
Mental Disorders (Third Edition Revised) criteria. Diagnosis
of probable or possible AD was based on the National Institute
of Neurological and Communicative Disorders and Stroke/
Alzheimer Disease and Related Disorders Association criteria.16
OUTCOME MEASURES
Five cognitive domains were assessed including (1) Memory:
total and delayed recall of the Selective Reminding Test17 and
the Recognition Subtest of the multiple-choice Benton Visual
Retention Test18; (2) Abstract Reasoning: Wechsler Adult In-
telligence Scale–Revised Similarities Subtest19; Identities and
Oddities Subtest of the Dementia Rating Scale20; (3) Visual-
Spatial: 5 items from the Rosen Drawing Test21; the matching
component of the multiple-choice Benton Visual Retention
Test18; (4) Language: 15-item Boston Naming Test22 and the
8 high-probability items from the Repetition Subtest and the
first 6 items of the Comprehension Subtest of the Boston Di-
agnostic Aphasia Examination22; and (5) Executive-Speed: mean
scores for phonemic fluency assessed by the Controlled Oral
Word Association Test and category fluency (Animals, Food,
and Clothing) mean scores.23
The 12 test scores were transformed into z scores. Means and
standard deviations were calculated from baseline scores for sub-
jects without dementia matched for age, race/ethnicity, and years
of education. The z scores were averaged within cognitive do-
mains, which were subsequently averaged to produce the com-
posite cognitive score.24 The outcome measure was the rate of
change in the composite score from diagnosis onward.
PREDICTOR VARIABLES
Baseline age, sex, race/ethnicity, and years of education were
collected by interview. Stroke was defined by World Health Or-
ganization criteria.25 Diabetes and hypertension were defined
based on self-report or documented treatment of either disor-
der at any time up to diagnosis of AD. Heart disease was de-
fined as a history of myocardial infarction, congestive heart fail-
ure, or angina pectoris at any time up to diagnosis of AD.
Fasting plasma total cholesterol and triglyceride concen-
trations were measured at a mean (SD) of 3.3 (2.2) years be-
fore diagnosis using standard enzymatic techniques. High-
density lipoprotein cholesterol concentrations were determined
after precipitation of apolipoprotein B–containing lipopro-
teins with phosphotungstic acid. Low-density lipoprotein cho-
lesterol concentrations were recalculated using the Friede-
wald formula.26 Because HDL-C and triglyceride values were
not normally distributed, log-transformed versions of these vari-
ables were used. Apolipoprotein E (APOE) genotype, deter-
mined using established methods,27 was available for 132 of the
156 participants (85%) and was classified on the basis of pres-
ence of at least 1 APOE-ε4 allele.
STATISTICAL ANALYSIS
Generalized estimating equations28 were used to examine the
relation of vascular factors to rates of cognitive change. By treat-
ing each subject’s repeated measures as a cluster, generalized











64 Not followed up
3749 Individuals excluded because
of CDR score of 0 or .5, prevalent AD,
or diagnosis of non-AD dementia
98 Individuals excluded because
of lipid data missing or collected
at or after diagnostic visit
163 Individuals with postdiagnosis
follow-up unavailable
Figure. Flowchart of analysis sample selection. AD indicates Alzheimer
disease; CDR, Clinical Dementia Rating Scale.
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estimating equations account for the correlation of repeated mea-
sures in the same individual. Two models were developed.
Model 1
Separate models were developed to assess the association of each
vascular variable (heart disease, stroke, diabetes, hyperten-
sion, smoking, and prediagnosis lipid concentrations) with post-
diagnosis cognitive decline. Taking diabetes as an example, the
dependent variable was the composite cognitive score, and pre-
dictor variables were diabetes, time (years), and a diabetes-
time interaction. Age at AD incidence, sex, race/ethnicity, years
of education (years), and study cohort were simultaneously in-
troduced into models. A significant diabetes effect would sug-
gest a diabetes-associated difference in cognition at diagnosis.
A significant time effect would suggest change in cognitive scores
over time regardless of diabetes status. A significant interac-
tion term would suggest differential rates of postdiagnosis cog-
nitive change associated with diabetes. The interval between
lipid measurement and AD incidence was included as a covar-
iate in the lipid models.
Model 2
To determine whether any vascular factor was independently
associated with cognitive decline, we constructed a post hoc
model that simultaneously included all variables associated with
cognitive decline after age- or multivariable-adjustment (cho-
lesterol concentrations and diabetes) (model 1), their interac-
tions with time, and demographic factors. Diabetes and LDL-C
and HDL-C concentrations but not total cholesterol concen-
tration were included in this model.
Supplementary Analyses
We repeated our analyses within APOE-ε4 strata in the sub-
sample with genotyping data (n=132). We also examined
whether use of lipid-lowering agents (LLAs) was associated with
cognitive decline and whether cholesterol concentrations pre-
dicted rate of decline similarly in LLA users vs nonusers.
RESULTS
Characteristics of the overall sample are given in Table1.
At diagnosis, most participants (93%) had a clinical de-
mentia rating of 1.0 (mild).29 The mean (SD) follow-up
time between diagnosis and last follow-up was 3.5 (2.2)
years (range, 1.0-10.3 years), with 1.6 (0.9) postdiag-
nostic assessments (range, 2-5).
PREDICTOR VARIABLES
AND BASELINE CHARACTERISTICS
There were no sex-related differences in predictor vari-
ables except for higher total cholesterol concentrations
in women (201.16 vs 184.53 mg/dL; P=.01). At diagno-
sis, non-Hispanic whites were, on average, 2.6 years older
than blacks (P=.26) and 3.4 years older than Hispanics
(P=.03). Prevalent disease variables (heart disease, stroke,
diabetes, and hypertension) did not vary by race/
ethnicity. Blacks had higher mean HDL-C concentra-
tions (55.3 mg/dL) compared with whites (43.8 mg/dL;
P=.004) and Hispanics (43.2 mg/dL; P .001) and lower
mean triglyceride concentrations (139.5 mg/dL) com-
pared with whites (207.1 mg/dL; P=.001) and Hispan-
ics (186.1 mg/dL; P .001). There were no differences
by race/ethnicity for sex, total cholesterol or LDL-C con-
centrations, or APOE-ε4 status (data not shown).
COGNITIVE DECLINE OVER TIME
A generalized estimating equation model indicated an
overall decline in composite cognitive score of 0.08 SD
per year (=−.08, P .001). A quadratic term for time,
added to the model to test whether cognitive change was
nonlinear, was nonsignificant.
VASCULAR FACTORS AND COGNITIVE DECLINE
Results of model 1 for each predictor are given in Table2.
Higher total cholesterol and LDL-C concentrations were
associated with faster cognitive decline. Each 10-mg/
dL–U increase in total cholesterol or LDL-C concentra-
tion was associated with an additional 0.10-SD decline
in cognitive score per year (P .001 for total choles-
terol and P=.003 for LDL-C) (to convert all types of cho-
lesterol to millimoles per liter, multiply by 0.0259). Nei-
ther HDL-C nor triglyceride concentration was associated
with cognitive decline. Of the medical history variables,
only diabetes was associated with faster decline (=−.05,
P=.045).
MODEL 2
In a post hoc model that simultaneously included HDL-C
and LDL-C concentrations and diabetes and their inter-
actions with time, only LDL-C was independently asso-
ciated with faster cognitive decline (Table 3).
Table 1. Characteristics of Patients




Age at diagnosis, mean (SD), y 83.0 (6.4)
Male sex, No. (%) 45 (28.8)
Years of education, mean (SD), y 6.6 (4.5)
Baseline cognitive score, mean (SD) −1.14 (0.56)
Race/ethnicity, No. (%)
Non-Hispanic white 14 (9.0)
Non-Hispanic black 46 (29.5)
Hispanic 94 (60.3)
Other 2 (1.3)
Cholesterol concentration, mean (SD), mg/dL
Total 196.4 (36.9)
Low-density lipoprotein 114.5 (34.6)
High-density lipoprotein 47.2 (14.3)




Heart disease 28 (17.9)
Stroke 24 (15.4)
Presence of at least 1 APOE-ε4 allele, No. (%) 43 (27.6)
Postdiagnosis follow-up, mean (SD), y 3.5 (2.2)
Abbreviation: APOE-ε4, apolipoprotein E ε4.
SI conversion factors: To convert all cholesterol to millimoles per liter,
multiply by 0.0259; triglyceride to millimoles per liter, multiply by 0.0113.
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SUPPLEMENTARY ANALYSES
In participants with genotype data, the presence of at
least 1 APOE-ε4 allele was associated with faster cog-
nitive decline (model 1) (multivariable-adjusted  for
interaction with time: =−.08, P=.05). The APOE-ε4–
stratified models revealed that in APOE-ε4 noncarriers
(n=89), higher prediagnosis total cholesterol, LDL-C,
and HDL-C concentrations were associated with faster
cognitive decline (multivariable-adjusted  for interac-
tions with time: total cholesterol, =−.001, P .001;
LDL-C, =−.001, P=.02; and HDL-C, =−.13, P=.01).
Triglyceride concentrations and medical history were
not associated with cognitive decline (data not
shown). Among APOE-ε4 carriers (n=41), higher total
cholesterol (=−.002, P=.03) and LDL-C (=−.002,
P= .03) concentrations and stroke (=−.18, P= .02)
and heart disease (=−.19, P= .001) were associated
with faster decline. No associations were seen with the
remaining vascular variables (data not shown).
The use of LLAs was not associated with rate of cog-
nitive decline. Models of the association of cholesterol
concentration with cognitive decline were repeatedly
stratified by use of LLAs, and results were similar (data
not shown).
COMMENT
There has been intense interest in identifying modifi-
able AD risk factors such as cardiovascular risk factors,
with the goal of preventing or at least delaying disease
onset.4 However, little attention has been given to the in-
fluence of these factors on disease progression. Cerebro-
vascular lesions, common in patients with AD, may ac-
celerate the clinical manifestation of AD.30 Vascular risk
factors may increase oxidative stress or activate a neu-
roinflammatory response, triggering amyloid produc-
tion. Thus, it has been suggested that AD and cerebro-
vascular disease may work synergistically to cause
cognitive decline.31
Consistentwithprevious research,32 we found thathigher
total cholesterol and LDL-C concentrations were associ-
ated with faster cognitive decline in patients with AD. An
earlier study of the Washington Heights/Inwood Colum-
bia Aging Project cohort found that higher total choles-
terol concentration was associated with lower risk of in-
cident AD.10 The prodromal stage of AD is associated with
decreased plasma cholesterol concentrations, possibly ow-
ing to dietary insufficiency and weight loss. By limiting the
present study to incident cases, we may have eliminated
bias or confounding in cholesterol concentrations associ-
ated with frailty and preclinical AD. This may explain the
difference with our findings for incident AD.
Lipid-lowering agents have previously been associ-
ated with slower cognitive decline in patients with AD.33
Nevertheless, consistent with others,13 we found no as-
sociation between LLAs and cognitive decline.
Of the medical history variables, only diabetes was as-
sociated with faster cognitive decline. Diabetes may in-
Table 2. Separate GEE Models Measuring Decline








 P Value  P Value
Total cholesterol .000 .95 −.001 .31
Time  total cholesterol, y −.001 .04 −.001 .03
HDL-C, log-transformed .35 .02 .22 .15
Time  HDL-C, y −.02 .61 −.06 .20
LDL-C, log-transformed .001 .70 −.001 .31
Time  LDL-C, y −.001 .04 −.001 .045
Triglyceride concentration,
log-transformed
−.17 .15 −.15 .22
Time  triglyceride
concentration, y
−.01 .66 −.006 .85
Diabetes −.11 .37 −.08 .46
Time  diabetes, y −.05 .03 −.05 .045
Hypertension −.21 .16 −.21 .14
Time  hypertension, y .01 .77 .000 .99
History of stroke −.03 .88 −.05 .77
Time  stroke, y −.045 .29 −.04 .31
History of heart disease .049 .69 .02 .91
Time  heart disease, y −.07 .07 −.06 .16
Ever smoked, baseline −.11 .28 −.04 .68
Time  ever smoked, y .03 .36 .03 .33
Abbreviations: GEE, generalized estimating equation;
HDL-C and LDL-C, high-density and low-density lipoprotein cholesterol,
respectively.
aAll models also included the following covariates, entered
simultaneously: time, age at incidence, sex, race/ethnicity, years of education
(years), and study cohort. Models for lipid variables additionally controlled
for and time between the lipid draw and dementia incidence. Significant
(P .05) coefficients are indicated in bold type.
Table 3. Post Hoc GEE Model Including Vascular Risk
Factors Significantly Associated With Cognition
in Individual Modelsa
Variable  (95% CI) P Value
Intercept −1.25 (−3.05 to 0.55) .17
Time, diagnosis onward, y .30 (−0.03 to 0.64) .08
Cohort, 1999 vs 1992 .008 (−0.10 to 0.11) .89
Age at diagnosis, per additional year −.01 (−.02 to 0.002) .11
Female sex .07 (−0.17 to 0.31) .55
Race/ethnicity
Non-Hispanic black −.22 (−0.67 to 0.23) .34
Hispanic −.292 (−0.733 to 0.150) .20
Years of education, per
additional year
.04 (0.02 to 0.06) .001
Time between lipid draw
and AD incidence, y
.003 (−0.05 to 0.06) .90
Cholesterol concentration
LDL-C .000 (−0.003 to 0.002) .67
Time  LDL-C −.001 (−0.002 to 0.000) .001
HDL-C, log-transformed .25 (−0.06 to 0.56) .11
Time  HDL-C −.06 (−0.14 to 0.02) .16
Diabetes history −.08 (−.30 to 0.13) .45
Time  diabetes history, y −.046 (−0.11 to 0.01) .14
Abbreviations: AD, Alzheimer disease; CI, confidence interval;
GEE, generalized estimating equation; HDL-C and LDL-C, high-density and
low-density lipoprotein cholesterol, respectively.
aSignificant factors associated with differential change in cognition over
time are indicated in bold type.
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fluence AD progression via an inflammatory mecha-
nism or by contributing to amyloid plaque and
neurofibrillary tangle formation.34 Heart disease, stroke,
hypertension, and smoking history were not associated
with disease progression in the overall sample.
The APOE-ε4 genotype may contribute to both vas-
cular disease and AD neuropathologic features, with ef-
fects of vascular risk factors more pronounced among
APOE-ε4 carriers.35 A previous study of this cohort found
faster cognitive decline in participants with mild AD who
wereAPOE-ε4 carriers.36 In ourAPOE-ε4–stratified mod-
els, higher total cholesterol and LDL-C concentrations
predicted faster decline in both groups, whereas history
of heart disease or stroke predicted faster decline in
APOE-ε4 carriers only.
Few studies have examined the simultaneous effects
of multiple vascular risk factors on AD progression. A
study of prevalent AD found that stroke but not other
vascular factors was associated with faster decline on the
Mini-Mental State Examination.13 A study of incident cases
found faster decline on the Clinical Dementia Rating Scale
and the Mini-Mental State Examination in those with a
history of atrial fibrillation, systolic hypertension, and an-
gina at baseline, and diabetes was associated with slower
decline.14 Our findings may differ from those of these stud-
ies for several reasons: (1) we measured cognitive change
using a comprehensive battery of cognitive tests, which
is potentially more sensitive than the Mini-Mental State
Examination; (2) one of the previous studies13 included
some participants with relatively advanced AD; and (3)
both of the previous studies were limited to whites, who,
on average, were more highly educated than our multi-
ethnic sample. In our post hoc model, only higher LDL-C
concentration emerged as an independent predictor. The
negative finding for diabetes as an independent predic-
tor may be to the result of reduced power in the post hoc
analysis because the  value associated with diabetes-
related cognitive change was similar to the diabetes-
specific model.
This study has limitations. Because disease history (heart
disease, stroke, and diabetes) was self-reported, the preva-
lence of these conditions in our sample was likely under-
estimated. Further, 44 of the participants with incident AD
were not included in this analysis because they died be-
fore the next follow-up assessment. Cause of death was un-
available; however, it is likely that many of these deaths
were due to vascular disease. If so, the effect size we found
may be an underestimate. We had only 1 lipid assess-
ment, potentially resulting in measurement error. Al-
though lipid concentrations were measured before diag-
nosis, some participants may have had prodromal AD. We
attempted to account for this by adjusting for the interval
between lipid measurement and diagnosis; results were un-
changed. Similarly, AD-associated reductions in blood pres-
sure may have masked an association between hyperten-
sion and disease progression that might have been noted
had blood pressure been measured at midlife. In future lon-
gitudinal studies, it would be better to measure these fac-
tors earlier in life. Our AD diagnoses were not neuropatho-
logically confirmed, and imaging was not consistently used
as part of the diagnostic process. Previous studies using mag-
netic resonance imaging and neuropathologic data sug-
gest that, especially in the oldest old, mixed dementia (AD
plus vascular dementia) is the most common cause of de-
mentia.37 Therefore, it is likely that some of our patients
with AD actually had mixed dementia. In addition, there
is always the possibility that our findings could be due to
chance.
Despite these limitations, clinical diagnosis was based
on uniform application of widely accepted criteria and, un-
like cognitive screening instruments used in some stud-
ies, our cognitive assessment comprised a comprehensive
battery of tests evaluating a range of cognitive domains. Our
use of a population-based sample limited to individuals with
incident AD reduced biases associated with convenience
samples (disease registries and hospital- or clinic-based
samples), which may not accurately reflect the course of
the disease in the general population.
In conclusion, we found that higher prediagnosis total
cholesterol and LDL-C concentrations and prevalent dia-
betes were associated with accelerated postdiagnostic cog-
nitive decline. History of heart disease or stroke was pre-
dictive of faster decline in APOE-ε4 carriers only.
Prevention or treatment of these conditions can poten-
tially slow the course of AD.
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